Gary P Kobinger

Summary

Affiliation: Public Health Agency of Canada
Country: Canada

Publications

  1. ncbi Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    J Infect Dis 201:1000-6. 2010
  2. ncbi Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 204:200-8. 2011
  3. ncbi Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection
    Ami Patel
    National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, Winnipeg, MB, Canada
    Vaccine 30:626-36. 2012
  4. ncbi Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S413-20. 2007
  5. ncbi Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5308. 2009
  6. ncbi Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Vaccine 25:5220-31. 2007
  7. ncbi Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus
    David Safronetz
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    J Virol 83:7285-95. 2009
  8. ncbi Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs
    Jason S Richardson
    Special Pathogens Department, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    J Infect Dis 204:S1032-42. 2011
  9. ncbi Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    Vaccine 27:3083-9. 2009
  10. ncbi Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:158ra146. 2012

Collaborators

Detail Information

Publications17

  1. ncbi Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    J Infect Dis 201:1000-6. 2010
    ..The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine...
  2. ncbi Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 204:200-8. 2011
    ..See the editorial commentary by Bausch, on pages 179-81.)..
  3. ncbi Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection
    Ami Patel
    National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, Winnipeg, MB, Canada
    Vaccine 30:626-36. 2012
    ..Overall, the data suggest that co-administering certain H5N1 antigens offer better or comparable protection to HA alone, however, combining extra antigens may be unnecessary and lead to unfavourable immune responses...
  4. ncbi Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S413-20. 2007
    ....
  5. ncbi Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5308. 2009
    ..The immune response elicited by this improved expression cassette vector (Ad-CAGoptZGP) and its ability to afford protection against lethal ZEBOV challenge in mice was compared to the standard Ad-CMVZGP vector...
  6. ncbi Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Vaccine 25:5220-31. 2007
    ..These data indicate that a heterologous adenovirus-based prime-boost vaccine strategy could safely stimulate strong immunity that may be needed for complete protection against SARS-CoV infection...
  7. ncbi Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus
    David Safronetz
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    J Virol 83:7285-95. 2009
    ..These observations set the stage for a more detailed characterization of the types of immunity required to protect humans from hantavirus infections...
  8. ncbi Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs
    Jason S Richardson
    Special Pathogens Department, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    J Infect Dis 204:S1032-42. 2011
    ..The humoral immune response was assayed to determine the effect of vaccine delivery route and preexisting immunity...
  9. ncbi Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    Vaccine 27:3083-9. 2009
    ..This study emphasizes the need to evaluate the relationship between both arms of the adaptive immune responses in regards to protective efficacy against influenza virus...
  10. ncbi Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:158ra146. 2012
    ..These results highlight the relevance of total ZGP-specific IgG levels as a meaningful correlate of protection against ZEBOV exposure...
  11. ncbi Recent advances in Ebolavirus vaccine development
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    Hum Vaccin 6:439-49. 2010
    ..Post-exposure protection is particularly important in outbreak and biodefense settings, as well as clinical and laboratory settings in the case of accidental exposure...
  12. ncbi Pentamers not found in the universal proteome can enhance antigen specific immune responses and adjuvant vaccines
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    PLoS ONE 7:e43802. 2012
    ..Overall, the data suggest that rare or non-existent oligopeptides can be developed as immunomodulators and supports the further evaluation of some 5-mer peptides as potential vaccine adjuvants...
  13. ncbi Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway
    James E Strong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada R3E 3R2
    Proc Natl Acad Sci U S A 105:17982-7. 2008
    ....
  14. ncbi Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada R3E 3R2
    Hum Gene Ther 18:413-22. 2007
    ..Spike-pseudotyped HIV-based vector is a novel lung-directed gene transfer vehicle that holds promise for the treatment of genetic lung diseases such as cystic fibrosis or alpha(1)-antitrypsin deficiency...
  15. ncbi Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates
    Jason S Richardson
    Special Pathogens Department, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Virol 87:3668-77. 2013
    ....
  16. ncbi Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies
    Xiangguo Qiu
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:138ra81. 2012
    ..These data highlight the important role of antibodies to control EBOV replication in vivo, and support the use of mAbs against a severe filovirus infection...
  17. ncbi Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, University of Manitoba, Winnipeg, Canada
    Virology 346:394-401. 2006
    ..These results validate further development of Chimpanzee-based vaccine and highlight the impact of pre-existing immunity to the vaccine carrier...